|
Rituximab maintenance versus retreatment: comparison of efficacy |
|||
| Maintenance |
Retreatment |
P |
|
|
|
|||
| Overall response rate (%) |
52% |
35% |
0.14 |
| Complete response rate (%) |
27% |
4% |
0.007 |
| % in continuous remission |
45% |
24% |
0.05 |
| % remaining in continuous remission |
23% |
2% |
0.03 |
| Median progression-free survival (months) |
31.7 |
7.4 |
0.007 |
| Median duration of rituximab benefit (months) |
31.7 |
27.4 |
0.94 |
Mohrbacher Arthritis Research & Therapy 2005 7(Suppl 3):S19 doi:10.1186/ar1739 |
|||